Concurrent Lenvatinib

ApprovedSmall molecule

Concurrent Lenvatinib is one of 352 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

351

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

ThymomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Classic Hodgkin LymphomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

GlioblastomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Lung CancerApproved

Active, not recruiting

ThymomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 3

Active, not recruiting

Classic Hodgkin LymphomaPhase 2

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Approved

5 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Concurrent Chemoradiotherapy

NCT06139419

Q3 2027

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT04453813

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT05062005

Phase 2Active, not recruiting

Glioblastoma

NCT04747145

Q4 2027

Phase 2Recruiting

Classic Hodgkin Lymphoma

NCT05949931

Q2 2028

Phase 2Recruiting

Cervical Cancer

NCT07439497

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma7 trials

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT05062005·447 enrolled

A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

Not yet recruiting·SSun Yat-sen University·N/A·NCT05622474·236 enrolled

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT07154069·802 enrolled

Show 4 more trials

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Recruiting·MMing-Yuan Chen·Phase 3·NCT07328841·456 enrolled

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06455410·216 enrolled

Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

Unknown status·SSun Yat-sen University·Phase 2·NCT03290820·184 enrolled

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT04453813·226 enrolled

Non-Small Cell Lung Cancer5 trials

Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT03006575·57 enrolled

Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04275687·35 enrolled

Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT04212052·104 enrolled

Show 2 more trials

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03745222·1 enrolled

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT07086456·80 enrolled

Small Cell Lung Cancer4 trials

Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

Terminated·SSun Yat-sen University·Phase 2·NCT03661567·52 enrolled

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT03659578·69 enrolled

Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02573506·99 enrolled

Show 1 more trial

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Completed· BeiGene logo

BeiGene·Phase 2·NCT04952597·126 enrolled

Cervical Cancer3 trials

Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT04583254·48 enrolled

Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer

Recruiting·SSamsung Medical Center·Phase 2·NCT07439497·34 enrolled

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03955367·638 enrolled

Lung Adenocarcinoma2 trials

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Completed·SSun Yat-sen University·Phase 2·NCT03904563·27 enrolled

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Unknown status·SSun Yat-sen University·Phase 2·NCT03905317·66 enrolled

20 more indications

Esophageal Squamous Cell Carcinoma2 trials

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT07086469·69 enrolled

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06912074·134 enrolled

Hypofractionated Radiotherapy2 trials

Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC

Completed·SSun Yat-sen University·Phase 2·NCT03900117·77 enrolled

Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI

Recruiting·SSun Yat-sen University·Phase 3·NCT06545747·490 enrolled

Pancreatic Cancer2 trials

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT01972919·23 enrolled

IORT Versus CCRT for Pancreatic Cancer

Unknown status·—·N/A·NCT02981641·100 enrolled

Induction Chemotherapy2 trials

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Recruiting·SSun Yat-sen University·Phase 3·NCT06675214·586 enrolled

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Recruiting·SSun Yat-sen University·Phase 3·NCT06092957·504 enrolled

Thymoma1 trial

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06730308·45 enrolled

Radiotherapy1 trial

Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC

Completed·SSun Yat-sen University·Phase 1·NCT04951063·18 enrolled

Classic Hodgkin Lymphoma1 trial

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Recruiting·SSun Yat-sen University·Phase 2·NCT05949931·108 enrolled

Chemotherapy1 trial

A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 3·NCT07400536·378 enrolled

Thymic Epithelial Tumor1 trial

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Unknown status·SSun Yat-sen University·Phase 2·NCT03663764·57 enrolled

Adenocarcinoma1 trial

A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum

Completed·TTrans Tasman Radiation Oncology Group·Phase 3·NCT00145769·326 enrolled

Esophageal Squamous Carcinoma1 trial

Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT06020885·18 enrolled

Lung Cancer1 trial

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Completed·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT00686322·6 enrolled

Rectal Cancer1 trial

Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07200141·156 enrolled

Locally Advanced1 trial

Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC

Unknown status·SSun Yat-sen University·Phase 2·NCT04524299·160 enrolled

Chemoradiotherapy1 trial

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Recruiting·SSun Yat-sen University·Phase 3·NCT07052669·311 enrolled

Trial1 trial

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

Recruiting·—·Phase 3·NCT06846450·470 enrolled

Concurrent Chemoradiotherapy1 trial

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled

Glioblastoma1 trial

Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT04747145·38 enrolled

Locally-advanced Rectal Cancer1 trial

Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Recruiting·SShandong Cancer Hospital and Institute··NCT06246344·128 enrolled

Immunotherapy1 trial

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

Recruiting·SSun Yat-sen University·Phase 3·NCT06041477·540 enrolled

Sources

References

[1]
ClinicalTrials.gov — 45 trial records for Concurrent Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concurrent Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concurrent Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Trans Tasman Radiation Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTrans Tasman Radiation Oncology Group

Concurrent Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma7 trials

Non-Small Cell Lung Cancer5 trials

Small Cell Lung Cancer4 trials

Cervical Cancer3 trials

Lung Adenocarcinoma2 trials

Esophageal Squamous Cell Carcinoma2 trials

Hypofractionated Radiotherapy2 trials

Pancreatic Cancer2 trials

Induction Chemotherapy2 trials

Thymoma1 trial

Radiotherapy1 trial

Classic Hodgkin Lymphoma1 trial

Chemotherapy1 trial

Thymic Epithelial Tumor1 trial

Adenocarcinoma1 trial

Esophageal Squamous Carcinoma1 trial

Lung Cancer1 trial

Rectal Cancer1 trial

Locally Advanced1 trial

Chemoradiotherapy1 trial

Trial1 trial

Concurrent Chemoradiotherapy1 trial

Glioblastoma1 trial

Locally-advanced Rectal Cancer1 trial

Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News